Wednesday May 30, 2012 0 comments
WESTMINSTER - Flagship Biosciences announced it has acquired IHCtech at the Colorado Anschutz Medical Campus.
Founded in 2002, IHCtech has developed a reputation for high-quality advanced immunohistochemistry procedures, meeting the IHC and histology needs of pharmaceutical and academic investigators.
"We have partnered with Flagship Biosciences on a number of new techniques and approaches for quantitation in immunohistochemistry," said Patsy Ruegg, IHCtech owner and founder. "Their approaches to whole slide analysis and commitment to quantitative pathology makes a perfect partner with IHCtech's expertise in high quality histology and immunohistochemistry."
"While Flagship Biosciences has established strong partnerships with a number of highly respected IHC laboratories both wining the United States and internationally, this acquisition gives us the opportunity to internally evaluate tissue staining and implement new processes that better equip immunohistochemistry operations for use in quantitative pathology with whole slide imaging analysis," said Dr. David Young, Flagship Biosciences president.